Atossa Therapeutics Announces Pricing of $50.0 Million Registered Direct Offering Priced At-The-Market
March 22, 2021 08:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, March 22, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (the “Company” or “Atossa”), a clinical-stage biopharmaceutical company seeking to discover and develop...
Atossa Therapeutics Announces Receipt of FDA Safe to Proceed Letter for Treatment of an Ovarian Cancer Patient with Oral Endoxifen Under Expanded Access Pathway
March 11, 2021 09:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, March 11, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19
February 25, 2021 09:00 ET
|
Atossa Therapeutics, Inc.
SEATTLE, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Accomplishments and Strategy for 2021
February 10, 2021 09:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa Therapeutics Announces Two-Year Update of FDA-Approved Expanded Access Treatment with Endoxifen
February 03, 2021 09:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa Therapeutics’ Phase 2 Endoxifen Breast Cancer Study Produces Substantially Positive Results Allowing Study to be Halted Early
February 02, 2021 09:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa Therapeutics Receives $21 Million from Recent Exercises of Outstanding Warrants
January 29, 2021 09:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Registration Is Now Open For Tribe Public’s Webinar Event “The Important Role of COVID Therapeutics in a Post-Vaccine World” Featuring Atossa Therapeutics’ CEO & CFO On February 2, 2021
January 27, 2021 09:00 ET
|
Atossa Therapeutics, Inc.
SEATTLE, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa Therapeutics President and CEO Dr. Steven C. Quay to Speak at Precision Medicine World Conference, Spotlighting Anthony S. Fauci, MD, Director NIAID January 25-27, 2021
January 25, 2021 09:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa Therapeutics Announces Pricing of $25.2 Million Registered Direct Offering Priced At-The-Market
January 06, 2021 09:15 ET
|
Atossa Therapeutics, Inc.
SEATTLE, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (the “Company” or “Atossa”), a clinical-stage biopharmaceutical company seeking to discover and develop innovative...